Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities

Podobne zapisy

• Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies
  od: VanDevanter, Donald R., i wsp.
  Wydane: (2017)
• Advancing clinical development pathways for new CFTR modulators in cystic fibrosis
  od: Mayer-Hamblett, Nicole, i wsp.
  Wydane: (2016)
• ASSOCIATION BETWEEN THE INTRODUCTION OF A NEW CYSTIC FIBROSIS INHALED ANTIBIOTIC CLASS AND CHANGE IN PREVALENCE OF PATIENTS RECEIVING MULTIPLE INHALED ANTIBIOTIC CLASSES
  od: Dasenbrook, Elliott C., i wsp.
  Wydane: (2014)
• Oral, Inhaled, and Intravenous Antibiotic Choice for Treating Pulmonary Exacerbations in Cystic Fibrosis
  od: Wagener, Jeffrey S., i wsp.
  Wydane: (2012)
• Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
  od: Mayer-Hamblett, N, i wsp.
  Wydane: (2020)